Compare Becton Dickinson and Co (BDX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Noble Corporation plc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Noble Corporation plc trades at $41.68 (market cap $6.65B). The key difference: Becton Dickinson and Co is far larger — about 6.2× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.8%). Which is the better fit depends on your goals.
| BDX | NE | |
|---|---|---|
Market Cap | $41.51B | $6.65B |
Sector | Health | Technology |
52-Week High | $185.39 | $54.37 |
52-Week Low | $135.49 | $25.70 |
Enterprise Value | $57.97B | $7.90B |
Dividend Yield | 2.79% | 4.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Noble Corporation (NE) trades at $41.79, up 4.55% with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $3.29B revenue, 7.17% net margin, and positive cash flow of $228M in 2025. Recent contract wins in Brunei and the UK Continental Shelf worth over $136M demonstrate operational momentum ahead of Q2 2026 earnings on July 27.
Analyst consensus suggests moderate upside with a $50 price target, though mixed earnings history and elevated P/E of 29.15 warrant caution. Key risks include offshore drilling market volatility and execution on new contracts, while institutional sentiment remains divided with 31% buy ratings versus 25% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
